8-K: Accuray Reports Mixed Q4, Strong FY25 Results; Issues FY26 Guidance

Accuray Incorporated announced its fourth quarter and fiscal year 2025 financial results, reporting strong annual revenue growth and adjusted EBITDA expansion, alongside a decrease in Q4 net revenue and net income.

Summary

• Net revenue for the fourth quarter of fiscal 2025 was $127.5 million, a decrease of 5% from the prior year period.
• Net income for the fourth quarter of fiscal 2025 was $1.1 million, compared to $3.4 million in the prior year period.
• Adjusted EBITDA for the fourth quarter of fiscal 2025 was $9.4 million, compared to $10.1 million in the prior year period.
• The order book-to-bill ratio for the fourth quarter was 1.2.
• Total net revenue for fiscal year 2025 was $458.5 million, an increase of 3% from the prior fiscal year, marking record annual revenue.
• Net loss for fiscal year 2025 was $1.6 million, a significant improvement from a net loss of $15.5 million in the prior fiscal year.
• Adjusted EBITDA for fiscal year 2025 was $28.3 million, an increase of 44% from $19.7 million in the prior fiscal year.
• The order book-to-bill ratio for fiscal year 2025 was 1.2.
• Service revenue increased 4% for both the fourth quarter ($56.8 million) and the full fiscal year ($220.9 million).
• Product revenue decreased 11% in the fourth quarter ($70.7 million) but increased 1% for the full fiscal year ($237.6 million).
• Successfully completed a refinancing of debt with a strategic partner.
• Ending order backlog as of June 30, 2025, was $427.0 million, 12.4% lower than at the end of the prior fiscal year fourth quarter.
• Cash, cash equivalents, and short-term restricted cash were $58.0 million as of June 30, 2025, a decrease of $20.8 million from March 31, 2025.

Sentiment

Score: 7

Explanation: While Q4 showed a dip in revenue and net income, the full fiscal year 2025 demonstrated strong growth in total net revenue, significant improvement in net loss, and substantial Adjusted EBITDA expansion. The successful debt refinancing and positive FY26 guidance contribute to a generally optimistic outlook, despite ongoing macroeconomic and tariff challenges.

Positives

• Fiscal Year 2025 net revenue increased 3% to $458.5 million, achieving record annual revenue.
• Fiscal Year 2025 net loss significantly improved to $1.6 million, compared to a $15.5 million net loss in the prior fiscal year.
• Fiscal Year 2025 Adjusted EBITDA increased 44% to $28.3 million, demonstrating strong operational performance.
• Service revenue showed consistent growth, increasing 4% for both the fourth quarter and the full fiscal year.
• Successfully completed a debt refinancing with a strategic partner invested in the company's long-term success.
• Operating expenses for fiscal year 2025 decreased by 2% to $139.1 million.
• Operating income for fiscal year 2025 was $7.8 million, a substantial increase from $0.5 million in the prior fiscal year.
• Received NMPA approval for Radixact SynC System and CyberKnife S7 System in China, expanding market access.

Negatives

• Total net revenue for the fourth quarter of fiscal 2025 decreased 5% to $127.5 million.
• Net income for the fourth quarter of fiscal 2025 decreased to $1.1 million from $3.4 million in the prior year period.
• Adjusted EBITDA for the fourth quarter of fiscal 2025 decreased to $9.4 million from $10.1 million in the prior year period.
• Product revenue decreased 11% in the fourth quarter of fiscal 2025.
• Operating expenses increased 10% in the fourth quarter of fiscal 2025.
• Ending order backlog as of June 30, 2025, was $427.0 million, representing a 12.4% decrease from the prior fiscal year fourth quarter.
• Cash, cash equivalents, and short-term restricted cash decreased by $20.8 million from March 31, 2025, to $58.0 million as of June 30, 2025.

Risks

• The global macroeconomic environment may negatively affect the operations of the company and its customers and suppliers.
• Disruptions to the supply chain, including increased logistics costs, could impact operations.
• The company's ability to achieve widespread market acceptance of its products is not guaranteed.
• Substantial outstanding indebtedness and the ability to maintain compliance with financial covenants related to debt pose financial risks.
• Enhanced international tariffs could adversely affect the company's financial performance.
• The company may not realize the expected benefits from its China joint venture and other partnerships.
• Risks inherent in international operations, including foreign exchange fluctuations and regulatory changes, could impact results.
• The company's ability to maintain or increase its gross margins on product sales and services is subject to market conditions and cost pressures.
• Delays in regulatory approvals or the development or release of new offerings could hinder growth.
• The company's ability to meet the covenants under its credit facilities is crucial for financial stability.
• The company's ability to convert its order backlog to revenue is subject to various factors, including customer readiness and installation timelines.

Future Outlook

For fiscal year 2026, total net revenue is expected in the range of $471 million to $485 million, representing a 3% to 6% increase year-over-year. Adjusted EBITDA is projected to be in the range of $31 million to $35 million, indicating a 10% to 25% increase year-over-year.

Management Comments

• "We continued to advance our strategy of innovation, access and service growth within the quarter and I am proud of how we navigated a challenging environment both within the quarter and for the fiscal year." Suzanne Winter, President and Chief Executive Officer.
• "In addition to annual revenue growth, strong service performance and adjusted EBITDA margin expansion, we successfully completed a refinancing of our debt with a strong partner that is invested in our long-term success." Suzanne Winter, President and Chief Executive Officer.
• "Our fourth quarter and full year financial results demonstrate the resilience of our team despite macroeconomic challenges and continuing tariff uncertainty." Ali Pervaiz, Chief Financial Officer.
• "We made steady operational progress while continuing to drive customer adoption through the expansion of our product portfolio." Ali Pervaiz, Chief Financial Officer.
• "We also announced refinancing plans with a partner committed to advancing our global business. I look forward to working with them, together with the global Accuray team, to execute on our core strategies for driving consistent growth." Ali Pervaiz, Chief Financial Officer.

Industry Context

Accuray operates in the specialized medical device industry, focusing on radiation therapy for oncology and neuro-radiosurgery. The company's emphasis on innovation, expanding patient access in growth markets (such as China, evidenced by NMPA approvals and the Tomo C system), and growing service solutions aligns with broader industry trends where medical device manufacturers seek to diversify revenue streams and penetrate emerging markets. The acknowledgment of macroeconomic challenges and tariff uncertainty reflects common headwinds faced by global players in this sector, highlighting the importance of resilient operational strategies and strategic partnerships.

Stakeholder Impact

• Shareholders: Likely positive impact from improved annual financial performance, successful debt refinancing, and positive FY26 guidance, though Q4 declines and decreasing backlog may introduce some caution.
• Customers: Benefit from continued innovation, expanded product portfolio (e.g., NMPA approvals for Radixact SynC and CyberKnife S7), and a focus on growing service solutions.
• Creditors: Positive impact from the successful debt refinancing with a strategic partner, indicating improved financial stability and a commitment to long-term success.
• Employees: Continued operational progress and strategic focus may provide stability and growth opportunities within the company.

Next Steps

• Execute on core strategies for driving consistent growth.
• Expand service revenue and margins.
• Expand installed base and revenue growth.
• Focus capital deployment to fuel innovation and shareholder value.
• Implement targeted initiatives to meaningfully expand Adjusted EBITDA.
• Host a conference call on August 13, 2025, to discuss results and recent corporate developments.
• Announce results for the first quarter of fiscal 2026.

Key Dates

Recommendation

The company demonstrated strong full-year performance with revenue growth and significant Adjusted EBITDA improvement, coupled with a successful debt refinancing and positive FY26 guidance. However, the fourth-quarter decline in revenue and net income, along with a decreasing order backlog, presents some near-term headwinds. The stock may be a 'hold' as investors assess if the company can consistently convert backlog to revenue and sustain growth amidst macroeconomic challenges, despite the positive strategic moves.

Keywords

Accuray, ARAY, financial results, Q4 2025, FY 2025, earnings, revenue, net income, adjusted EBITDA, debt refinancing, medical devices, radiation therapy, oncology, neuro-radiosurgery, China joint venture, NMPA approval, Radixact, CyberKnife